Department of Ophthalmology, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, 2630 Sugitani, Toyama, 930-0194, Japan.
Jpn J Ophthalmol. 2012 Mar;56(2):159-64. doi: 10.1007/s10384-011-0114-3. Epub 2012 Jan 14.
We examined the predictive factors for final visual acuity (VA) with macular edema of branch retinal vein occlusion (BRVO) treated by intravitreal injection of bevacizumab (IVB) and examined the differences between patients without recurrent macular edema due to BRVO after a single IVB and patients treated with multiple IVB because of recurrent macular edema.
In this retrospective study, 37 eyes of 37 patients with BRVO were treated with IVB and followed up for more than 24 weeks. Eighteen eyes showed no recurrence of macular edema after a single IVB (single IVB group). The remaining 19 eyes showed recurrent macular edema and underwent multiple IVB (multiple IVB group). VA and morphologic parameters of optical coherence tomography were examined.
Mean VA, central retinal thickness, and mean retinal thickness in a circular region of 1-mm diameter at the fovea improved significantly with IVB treatment in both groups. Final VA was correlated with baseline VA and integrity grade of the photoreceptor inner and outer segment (IS/OS) line beneath the fovea.
Baseline VA and IS/OS line grade at 4 weeks may be predictive factors for final VA.
我们研究了接受玻璃体内注射贝伐单抗（IVB）治疗的视网膜分支静脉阻塞（BRVO）伴黄斑水肿患者最终视力（VA）的预测因素，并比较了单次 IVB 治疗后 BRVO 无黄斑水肿复发患者和因黄斑水肿复发而接受多次 IVB 治疗患者之间的差异。
在这项回顾性研究中，37 例 BRVO 患者的 37 只眼接受了 IVB 治疗，并随访超过 24 周。18 只眼在单次 IVB 后无黄斑水肿复发（单次 IVB 组）。其余 19 只眼出现黄斑水肿复发，并接受了多次 IVB（多次 IVB 组）。检查 VA 和光相干断层扫描的形态学参数。
两组患者的平均 VA、中心视网膜厚度和黄斑中心 1mm 直径圆形区域的平均视网膜厚度均随着 IVB 治疗而显著改善。最终 VA 与基线 VA 和黄斑下感光细胞内、外节（IS/OS）线的完整性分级相关。
基线 VA 和 4 周时的 IS/OS 线分级可能是最终 VA 的预测因素。
